Shenzhen Zhongge Biotechnology Co. Ltd. has divulged AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, type 2 diabetes, diabetic nephropathy, dyslipidemia and obesity.
Maze Therapeutics Inc. has divulged apolipoprotein L1 (APOL1) inhibitors reported to be useful for the treatment of chronic kidney disease, focal segmental glomerulosclerosis, diabetic retinopathy, diabetic HIV-associated nephropathy, lupus nephritis, pre-eclampsia and sepsis.
Arbor Biotechnologies Inc.’s ABO-101 has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of primary hyperoxaluria type 1 (PH1).
Newco Linkgevity Ltd. has won backing from the KQ Labs accelerator program at the Francis Crick Institute in London, enabling it to take forward the lead program, an anti-necrotic drug for treating acute kidney injury, and to further develop its AI-driven system for identifying aging-related therapeutic targets. Alongside access to the Crick’s expertise in translational research and in shaping academic science to make it investible, companies joining KQ Labs receive an equity investment.
Acute kidney injury (AKI) may progress to chronic kidney disease, and there is an urgent need for approaches that improve the limited regeneration of the renal tubules after AKI.
Accunea Ltd. is looking to reduce the number of kidneys that are discarded with its bioanalysis technology Renosure, which can detect critical changes in organ function in real-time, both before and after transplantation. The company is looking to raise £1.6 million (US$2 million) to develop the device which could transform the lives of people requiring a kidney transplant.
Kidney stones are largely composed of calcium oxalate (CaOx), which can cause serious renal inflammation and damage to renal tubular epithelial cells, with the CaOx crystals gradually accumulating and leading to CaOx nephrocalcinosis.
Researchers from Hokkaido University of Science presented data from a study that aimed to assess the impact of reverse erythroblastosis virus (REV)-ERBα agonist, SR-9009, on renal fibrosis.
Climb Bio Inc. has entered into an exclusive license agreement with Beijing Mabworks Biotech Co. Ltd. for rights to develop and commercialize MIL-116 (now CLYM-116), an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy, in the territory outside of Greater China.
RSS
